EverHint – Momentum Swing — Volatile High Beta for Apr 15, 2026 – 5 Signals – Healthcare Leads (4)

What This Signal Is (Quick)

Volatile High Beta is a momentum swing trading strategy focused on High volatility stocks (60%+) - for risk-tolerant traders.

Signal Type: Breakout (momentum continuation)

What Makes This Signal:

• Stock showing strong momentum near or at highs
• Increased volume confirms institutional interest
• Breaking out or consolidating near resistance
• High volatility stocks (60%+) - for risk-tolerant traders

Ideal For: Risk-tolerant traders comfortable with high volatility and large price swings

Key Criteria:

• Strong RSI momentum (configurable thresholds)

• Volume surge above average

• Price momentum confirmation

• Minimum ADV: $25M+ (varies by variant)

• Earnings buffer: 7 days pre/post earnings

• Variant-specific filters applied

Holding Period: 1-4 weeks
Risk Level: Medium-High

How We Ranked Today

Ranked by composite momentum score (higher = stronger momentum)

📊 Momentum Swing — Volatile High Beta Signals (5 Total)

Ranked by score:

Field Notes

Sector concentration: Healthcare (4), Communication Services (1)

Insider selling: TVTX (Travere Therapeutics, Inc., $-4.7M), SYRE (Spyre Therapeutics, Inc., $-1.5M), RVMD (Revolution Medicines, Inc., $-3.2M)

Data coverage: 60.0% insider, 0.0% congressional, 100.0% earnings, 100.0% analyst, 80.0% news

Peer Analysis

Understanding how these stocks relate to their industry peers:

TVTX (Travere Therapeutics, Inc.): Leads 10 peers: CGON ($67.68, +0.6%), TARS ($71.80, -2.7%), CELC ($123.47, +2.2%), XENE ($58.88, -0.8%), CNTA ($39.61, +0.1%) | Peer of: ARQT ($24.58, -2.0%), CELC ($123.47, +2.2%), CGON ($67.68, +0.6%) and 9 more

RVMD (Revolution Medicines, Inc.): Leads 9 peers: BBIO ($77.70, -0.3%), IONS ($76.82, +0.1%), EXEL ($44.28, -3.5%), MRNA ($54.26, +2.7%), BMRN ($55.27, -0.4%) | Peer of: ASND ($241.71, -3.2%), BBIO ($77.70, -0.3%), BMRN ($55.27, -0.4%) and 13 more

GSAT (Globalstar, Inc.): Leads 6 peers: TKC ($6.44, +0.3%), TDS ($44.68, -1.8%), PHI ($20.53, -0.6%), LUMN ($8.59, +10.1%), MSGS ($334.80, -1.4%) | Peer of: MSGS ($334.80, -1.4%), NXST ($196.59, +1.3%), TKC ($6.44, +0.3%)

AVNS (Avanos Medical, Inc.): Leads 9 peers: VREX ($11.78, +0.3%), CTKB ($4.69, +1.5%), CLPT ($10.46, +0.8%), PACB ($1.60, +1.9%), CYH ($3.15, +2.6%) | Peer of: BVS ($10.56, +6.6%), CLPT ($10.46, +0.8%), CMPS ($5.96, +3.6%) and 8 more

SYRE (Spyre Therapeutics, Inc.): Leads 10 peers: PHVS ($29.14, +1.6%), IMNM ($23.39, +2.1%), WVE ($7.59, +2.7%), NTLA ($14.94, +1.1%), ZYME ($27.73, +2.8%) | Peer of: ABCL ($3.86, +2.7%), ARDX ($6.30, -0.5%), AZTA ($24.95, +2.8%) and 12 more

Recent Headlines

AVNS (Avanos Medical, Inc.)

• Avanos Medical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avanos Medical, Inc. - AVNS (source)
• Avanos Stock Surged on $1.27 Billion AIP Buyout Deal at 72% Premium (source)
• Avanos Medical Inc (AVNS) Stock Up 69.5% but GF Value Says Overvalued -- GF Score: 73/100 (source)
• This Healthcare Stock Is Rising 69%. It's Getting Bought Out for a Big Premium. (source)
• $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avanos Medical, Inc. (NYSE: AVNS) (source)
• Shareholder Alert: Ademi LLP investigates whether Avanos Medical Inc. is obtaining a Fair Price for Public Shareholders (source)
• AVNS Stock Alert: Halper Sadeh LLC is Investigating Whether Avanos Medical, Inc. is Obtaining a Fair Price for its Shareholders (source)
• AIP to take Avanos Medical private in a deal valued at about $1.27 billion (source)
• Avanos Medical, Inc. Agrees To Be Acquired by American Industrial Partners for Approximately $1.272 Billion (source)

RVMD (Revolution Medicines, Inc.)

• Revolution Medicines: 'Strong Buy' On Daraxonrasib Win And Expansions Underway (source)
• RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data (source)
• Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes (source)
• Revolution Medicines (RVMD) Hits All-Time Highs After Groundbreaking Cancer Trial Results (source)
• How This Biotech Stock Skirted Today's Selloff (source)
• Revolution Medicines surges 38% as pancreatic cancer drug shows breakthrough (source)
• Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo (source)
• Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial (source)
• This Biotech Stock Soars 38%. Pancreatic Cancer Trial Was a Success. (source)
• Stock Market Live April 13: S&P 500 (SPY) Back in the Red as Oil Gushes Higher (source)
• Revolution Medicines' experimental cancer pill helps improve survival in late-stage study (source)
• Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial (source)
• Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer (source)

SYRE (Spyre Therapeutics, Inc.)

• Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up Following Analyst Upgrade (source)
• Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock (source)
• Spyre Therapeutics: Strong SPY001 Data Set Up A Catalyst-Rich 2026 (source)
• Spyre Therapeutics Announces Proposed Public Offering of its Common Stock (source)
• Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Transcript (source)
• Spyre Therapeutics Breaks Higher On Positive Data From Ulcerative Colitis Drug (source)
• Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients (source)
• Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026 (source)

TVTX (Travere Therapeutics, Inc.)

• Travere Therapeutics: Re-Rating Potential As Filspari Wins Full Approval (source)
• TVTX Stock Soars on FDA Nod for Filspari in Second Kidney Indication (source)
• Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock? (source)
• Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (source)
• FDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease Patients (source)
• FDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease Patients (source)
• Travere Therapeutics Stock Skyrockets On FDA Approval (source)
• Travere Therapeutics Stock Skyrockets On FDA Approval (source)
• Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS Transcript (source)
• Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS Transcript (source)
• US FDA expands approval for Travere Therapeutics' drug for rare kidney disease (source)
• US FDA expands approval for Travere Therapeutics' drug for rare kidney disease (source)
• Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS (source)
• Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS (source)
• Roy Baynes Sells 10,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock (source)

Market Context

The broader market shows a mixed but predominantly risk-on tone, with the Nasdaq advancing 1.59% and the S&P 500 gaining 0.79%, while the Dow edges lower by 0.15%. This divergence suggests robust momentum in growth-oriented segments, favoring high beta strategies that thrive on intraday swings and trend continuation. For a momentum swing approach targeting volatile high beta names, the overall uptrend in key indices supports signal viability, particularly as investor risk appetite appears tilted toward higher-reward opportunities despite the Dow's cautionary pullback.

Volatility remains moderate at a VIX of 18.06, down 1.63%, which tempers extreme intraday gyrations but still provides sufficient movement for swing trades in high beta assets. Declining volatility reduces tail risks, allowing momentum signals to capture cleaner directional moves without excessive whipsaws, though traders should monitor for any VIX rebound that could amplify swings in volatile names.

Healthcare's prominence as the top sector amid this rotation hints at defensive undertones blending with momentum plays, as investors pivot from lagging areas like those reflected in the Dow. This setup enhances the strategy's edge, with five total signals poised to leverage sector strength in a market balancing growth enthusiasm and stability.

Vlad's Take (EverHint)

Today's signals: Strong sector concentration in Healthcare (4 signals) suggests sector-specific rotation. 3 signals showing insider selling warrant caution.

Sharing Call-to-Action

✅ If this added value to your research, consider liking, sharing, or subscribing. It genuinely helps.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/